Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV-1 Who Have Maintained an Adequate Response to ART

X
Trial Profile

A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV-1 Who Have Maintained an Adequate Response to ART

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vacc-4x (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Bionor Holding; Bionor Pharma
  • Most Recent Events

    • 29 Jan 2018 According to a Bionor media release, Bionor Pharma changed its name to Bionor Holding.
    • 13 Jun 2016 According to Bionor Pharma media release, Bionor had a collaboration with SCHARP since 2014 with the purpose of performing a post-hoc statistical analysis of data from this trial.
    • 13 Jun 2016 Results published in Bionor Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top